Clin Mol Hepatol.  2021 Jul;27(3):402-412. 10.3350/cmh.2021.0179.

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma

  • 1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
  • 2The Catholic University Liver Research Center, Seoul, Korea
  • 3Department of Gastroenterology, Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seou, Korea
  • 4Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea
  • 5Yonsei Liver Center, Severance Hospital, Seoul, Korea


Over the past several decades, entecavir (ETV) and tenofovir disoproxil fumarate (TDF) have remained the first-line antiviral agents in several international guidelines. These two antiviral agents have shown similar short to intermediateterm efficacy, including virologic, biochemical, serologic, and histologic responses. However, huge controversies regarding the antiviral efficacy of ETV and TDF in preventing the development of hepatocellular carcinoma (HCC) still exist. In this review, we summarized recent studies that compared the treatment efficacy of ETV and TDF in terms of HCC development.


Entecavir; Tenofovir; Hepatitis B; Carcinoma, Hepatocellular; Efficacy; Outcome
Full Text Links
  • CMH
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: